Scientists Confront the Social Stakes of Epigenetic Editing and Environmental Health

At the 2024 Clinical Epigenetics International Conference, known as CLEPIC, a remarkable experiment in scientific self-examination took place. Rather than presenting new data on DNA methylation or chromatin remodeling, attendees were asked to step back from their benches and confront a set of uncomfortable questions: When is epigenetic knowledge good enough for the clinic? When can it justify banning a chemical? And who bears responsibility when the answers remain unclear? A newly published meeting report in Epigenetics Communications, authored by Michelle Habets of the Rathenau Instituut, Marianne Rots of the University of Groningen, and Luca Chiapperino of the University of Lausanne, documents these round table discussions and distills them into an agenda that could shape how the epigenetics community translates its science into medicine and policy.

The round tables were designed around the framework of Responsible Research and Innovation, or RRI, an approach that has gained traction over the past decade in both academia and science policy. Unlike traditional ethical, legal, and social implications research, which treats ethics as an external check on finished technologies, RRI asks scientists to embed social and ethical reflection into the earliest stages of research itself. This is no small ask. Studies cited in the report show that many natural scientists see themselves as responsible only for the quality of their research, viewing societal consequences as the domain of regulators and oversight bodies operating downstream in a linear model of innovation. The term responsibility, researchers have found, can even be perceived as accusatory by scientists who feel that RRI policies are imposed by outsiders unfamiliar with the realities of laboratory work.

To avoid these pitfalls, the organizers built the discussions around two concrete case studies tailored to the actual technical frontiers of epigenetics. Ten tables of roughly eight participants each, moderated and blended across seniority, gender, and research interests, spent forty minutes debating guided vignettes before their note-takers submitted minutes for thematic analysis. The first case examined whether epigenetic editing, a nascent family of technologies that rewrites gene expression without altering the DNA sequence, is ready to move from bench to bedside. The second probed whether environmental epigenetics, the study of how exposures shape chemical tags on the genome, is mature enough to inform regulatory risk assessment of chemical safety.

The clinical case centered on a striking proof-of-principle published in Nature in 2024. Using lipid nanoparticles to deliver a so-called hit-and-run epigenetic editor, researchers silenced the Pcsk9 gene in mice, stably reducing plasma cholesterol for eleven months without the editor persisting in the cells. The promise is obvious: a one-time therapy that could replace daily statin adherence, which is undermined by forgetfulness, side effects, and poor awareness. Round table participants largely agreed that a single-administration therapy would be preferable to recurrent medication, provided safety and efficacy standards were met. Yet the conversation quickly grew more complicated. One group argued that epigenetic editing should only become a standard treatment if it offers clear additional benefits over existing drugs. Others questioned the economics, noting that the global statin market was valued at over sixteen billion dollars in 2023 and suggesting that biotechnology companies may simply be eyeing a shift of pharmaceutical profits rather than genuine cost savings for patients.

Beneath the commercial questions lay deeper scientific uncertainties. Participants agreed that knowledge of the long-term and off-target effects of epigenetic editing is far too thin for clinical deployment. Delivery of synthetic editors into cells remains problematic, and little is known about how editing behaves differently across cell types. Stability of the induced modifications, a precondition for any durable therapy, has been demonstrated only in limited windows, and cells may well fight back to restore their original epigenetic state, potentially requiring regular epigenome and transcriptome monitoring. Reversibility is equally underexplored, yet participants considered it essential: clinicians would need the ability to revert cells to their original state should severe side effects emerge. Some groups raised the specter of cancer or autoimmune responses, and while a few speculated about impacts on future generations, the participants emphasized that no consensus exists on intergenerational epigenetic inheritance in humans.

The discussions also surfaced concerns about equity and biological complexity. Without diverse reference epigenomes, widespread therapeutic editing could accrue existing health inequalities, a risk participants proposed to mitigate through more diverse basic research, representative clinical trials, and parallel development of alternative treatments. Two groups cautioned against simplistic views of safety, warning that even an on-target edit could trigger a domino effect through regulatory networks, with downstream consequences for genes far removed from the intended target. Yet one participant pushed back with a pointed rhetorical question about a double standard: do we know the on-target systemic effects of aspirin, and if not, why should epigenetic technologies be held to a stricter evidentiary bar than established drugs? In an unprompted turn, several groups also discussed public outreach, worrying that patients might be frightened by the phrase gene editing and suggesting the technology may even need a new name.

The second case, on environmental epigenetics and chemical regulation, produced an even more sobering assessment. Participants from six tables found common ground that current epigenetic evidence is not ready to support the regulation or prohibition of substances. There are no known unique epigenetic signatures for specific exposures, and the same stress response can be triggered by different chemicals, making it nearly impossible to dissect the contribution of any single component of a person’s exposome. No standardized methods exist to establish what minimal epigenetic change can be meaningfully interpreted as functional disease risk, so results are hard to interpret and difficult to reproduce. Tissue access compounds the problem: researchers can mostly measure blood, swabs, urine, and feces, even though organs like the brain, highly relevant to stress research, remain inaccessible, and different tissues react differently to chemicals. Animal models offer only limited translational value because of differing lifespans and epigenetic drift.

Challenges inherent to epigenetic biology itself deepened the pessimism. Genetic background can confound exposure studies, as illustrated by a 2017 finding that children carrying a common PON1 gene variant showed adverse cardio-metabolic methylation profiles only when prenatally exposed to pesticides, implying that identical exposures produce different risk profiles depending on the individual. Route of intake, dose chronology, exposure windows from pregnancy to old age, and interacting contexts like the microbiome, diet, and socioeconomic status all modulate epigenetic effects, which are themselves small against multifactorial disease backgrounds. Participants questioned whether statistical epigenetic data would even add value beyond existing epidemiological correlations, and they flagged societal risks of their own science: stigmatization of prospective parents, echoing what pregnant smokers already face, and the potential misuse of epigenetic data by insurers, a scenario participants urged governments to regulate proactively. As a path forward, groups called for standardized methods, large prospective cohorts, bioinformatic integration of heterogeneous data, and honest debate about whether the community has a responsibility to push epigenetic testing into regulatory science, even as the tobacco saga shows policymakers can resist decades of harm evidence.

Perhaps the report’s most striking finding is the divergence of views on what all this means for translation. One camp sees the field’s immaturity as a solvable practical challenge, pointing to accumulating safety data on editing platforms and the slow advance of epigenetic endpoints in toxicology. A second, more cautious group doubts that data harmonization and standardization can ever fully succeed. A third views the complexity of the epigenome, shaped by environment, stochasticity, and gene-environment interplay, as a fundamental barrier that no methodology will overcome, rendering cause-and-effect disentanglement effectively impossible. Meanwhile, a few participants questioned whether demanding complete knowledge before translation is an unreasonable standard at all, noting that two epigenetic editing clinical trials have already received medical-ethical approval. The authors tentatively attribute these splits to differences between basic and translational researchers, to hype dynamics driven by venture capital, and to competitive pressures in the market economy.

From these tensions, the report’s authors extract a three-part agenda. First, the field must explicitly discuss what kinds of knowledge it deems necessary before clinical or regulatory translation, openly interrogating how much of the rush toward epigenetic innovation reflects informed judgment versus hype and a race for startup capital. Second, widely accepted methodological and analytical standards are needed to bridge basic science and application, a mission the International Society for Molecular and Clinical Epigenetics has begun promoting through interdisciplinary dialogue. Third, and most notably, the round tables revealed a largely untapped reflexivity among scientists, who are fully aware of the tension between complete mechanistic understanding and pragmatic innovation, yet rarely given structured forums to confront it. The CLEPIC round tables will become a regular conference feature, and the authors argue that such collaborative spaces, where natural and social scientists interrogate assumptions together, are an essential first step toward responsible epigenetic research and innovation, with reflexivity working in both directions.

Subject of Research: Societal and ethical readiness of epigenetic editing for clinical use and environmental epigenetics for regulatory risk assessment

Article Title: Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24

Article References: Habets, M. G., Rots, M. G., & Chiapperino, L. (2025). Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24. Epigenetics Communications, 5(1), Article 4. https://doi.org/10.1186/s43682-025-00035-1

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00035-1

Keywords: epigenetics, epigenetic editing, responsible research and innovation, environmental epigenetics, precision environmental health, personalized medicine, chemical risk assessment, DNA methylation, CLEPIC24, science policy, statins, PCSK9